

Sangair update– May 2024

Sangair team can share some exciting news.

Our ongoing pre-clinical study shows a clear effect. SangAspet™ lowers the number of viable bacteria (*Pseudomonas Aeruginosa*) in blood with average 52%, results achieved so far...

Simultaneously, the oxygen gas levels increase as well, which is believed to be beneficial to the patient.

The difference between the treated group of animals compared to the non-treated group of animals is not yet ready, but the trials are ongoing.

Other updates

Sangair have a strong patent family, approved in each country where applied. Most recently the patents were approved in Japan and Canada.

Boosted by the positive results from pre-clinical study, Sangair will now accelerate development of the SangAsept™ system by recruitment of critical competencies.

If interested in learning more of the technology and the future treatment, or if interested in investing in Sangair, please don't hesitate to contact us.

Sincerely,
Henrik Rundgren, CEO

About Sangair

Sangair develops an innovative supportive medical device, SangAsept™ for treatment of sepsis patients.

This device can support the healthcare by lowering bacteria present in blood as well as stimulating the patient's immune system.

The aim is to stabilize patient health and possibly to shorten hospital stay associated with an infection and a potential sepsis.



Founder Johan Sjöholm operates the pilot version of a SangAsept™ system